前收市價 | 13.58 |
開市 | 13.87 |
買盤 | 13.65 x 400 |
賣出價 | 13.69 x 200 |
今日波幅 | 13.38 - 13.91 |
52 週波幅 | 10.92 - 59.99 |
成交量 | |
平均成交量 | 1,050,773 |
市值 | 823.892M |
Beta 值 (5 年,每月) | 0.85 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -8.39 |
業績公佈日 | 2024年4月25日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 22.06 |
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -10.43% and 28.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.